Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PREP | P48147 | 3/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010269 | 0.91 | CYP1A2 (0.54) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL16838718 | 0.85 | CHRM2 (0.38) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL7665343 | 0.81 | CHRM2 (0.36) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL29642341 | 0.80 | CHRM2 (0.46) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL1012317 | 0.80 | CHRM2 (0.46) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL797568 | 0.80 | CHRM2 (0.46) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL15239620 | 0.80 | CHRM2 (0.46) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL31534303 | 0.77 | CHRM2 (0.38) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL31608720 | 0.77 | CHRM2 (0.38) | CYP1A2HIF1ACHRM2CHRM1CHRM3 | |
| SCHEMBL30680871 | 0.77 | CHRM2 (0.38) | CYP1A2HIF1ACHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008068-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2020-12-30 | — | — | EP | disclosed |
| EP-2935263-B1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-05 | — | — | EP | disclosed |
| US-9505769-B2 | Tetraaza-cyclopenta[a]indenyl derivatives | ASCENEURON SA (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20160137648-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2016-05-19 | — | — | US | disclosed |
| EP-3008068-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | Asceneuron SA (CH) | 2016-04-20 | — | — | EP | disclosed |
| EP-2935263-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8962611-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2014198808-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2014-12-18 | — | — | WO | disclosed |
| EP-2813505-A1 | Tetraaza-cyclopenta[a]indenyl derivatives | Asceneuron SA (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-8907095-B2 | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 | MERCK SHARP & DOHME CORP. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-12-04 | — | — | US | disclosed |
| US-8846657-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | MERCK SHARP & DOHME LLC | 2014-06-26 | — | — | US | disclosed |
| WO-2014100065-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
| US-7595327-B2 | Exo-N-Hydroxy-3-[methyl({4-[(2-methylquinolin-4-yl) methoxy]phenyl}sulfonyl)amino]bicyclo[2.2.1]heptane-2-carboxamide; rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, ankylosing spondylitis, psoriasis, osteoarthritis, tumor metastasis, sepsis, AIDS, ulcerative colitis, multiple sclerosis | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-09-21 | — | — | US | disclosed |
| US-6384228-B2 | EPIBATIDINE; ANALGESICS; ANIMAL EXTRACTS | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | SI, MMP12, TNF | CYP1A2 861/4885HIF1A 103/4885CHRM2 2768/4885 |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | DDX21, ING2, MDM2 | CYP1A2 2648/4885HIF1A 2894/4885CHRM2 4873/4885 |
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | DHPS, ALAD, HAAO | CYP1A2 163/4885HIF1A 2351/4885CHRM2 4586/4885 |
| US-20160137648-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | CHRM1, CHRM2, CHRM3 | CYP1A2 640/4885HIF1A 3112/4885CHRM2 2/4885 |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | DDX21, ING2, MDM2 | CYP1A2 2648/4885HIF1A 2894/4885CHRM2 4873/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | CYP1A2 1398/4885HIF1A 801/4885CHRM2 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.